一分钟看懂
这是一项关于结直肠癌的II 期研究，登记的药物或干预包括PD-1 inhibitor；CTLA-4 inhibitor；ctDNA/MRD testing；Curative Surgery，当前状态为招募中。登记地点显示中国上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
PD-1 inhibitor；CTLA-4 inhibitor；ctDNA/MRD testing；Curative Surgery · II 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁至75 岁；另列出7项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Fudan University Shanghai Cancer Center · 上海
公开的入选条件
- * Written informed consent obtained before any study-related procedures.
- * Age 18 to 75 years, inclusive.
- * Histologically confirmed colon adenocarcinoma, mucinous adenocarcinoma, or signet-ring cell carcinoma, with the tumor located at least 15 cm from the anal verge.
- * dMMR/MSI-H status confirmed by immunohistochemistry, polymerase chain reaction, or next-generation sequencing.
- * Eastern Cooperative Oncology Group performance status of 0 or 1 and an expected survival of at least 3 months.
- * Adequate hematologic, hepatic, renal, coagulation, thyroid, and cardiac function, as defined in the protocol.
- * Negative pregnancy test for women of childbearing potential; agreement to use highly effective contraception, when applicable.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07841236；登记信息更新于 2026-09-25。